Business Standard

SPONSORED CONTENT

What's this ?

Sponsored Content is a "Paid For" Press Release distribution arrangement. Purely a Commercial Arrangement, brands and advertisers pay to be featured and to get this content published.

The Editorial/Content team at Business Standard has not contributed to writing/editing this article.

To get your brand featured in this Section write to assist@bsmail.in

Dr. Manjiri Bakre awarded 'Health Tech Innovator of the Year'

ANI Press Release 

Tennis player James Blake
Dr Manjiri Bakre

Bengaluru (Karnataka) [India], September 24 (ANI/NewsVoir): Dr Manjiri Bakre, Founder & CEO OncoStem Diagnostics, was awarded 'Health Tech Innovator of the Year' by ET Healthworld - Intelligent Health & Tech awards 2020.

ET Healthworld.com's Intelligent Health & Tech Awards 2020 (IHTA) honours hard work, innovation and excellence of healthcare-focused AI & Tech enterprises and individuals across 30 plus categories in a number of functional areas like telemedicine services, m-health applications and medical device innovation.

It provides a platform to the game changers, innovators and achievers of AI & Tech companies, who have shown exemplary performance and have aided the growth of the healthcare industry, to claim their fame and inspire others to outshine them. Screening of applications was conducted by KPMG and some of the jury members were Dr Atul Mohan Kochhar, CEO, NABH; Dr Girdhar J Gyani, (Jury Chair), Director General, Association of Healthcare Providers India; Rakesh Mishra, Director, CSIR-CCMB Ministry of Science & Technology, Government of India and others.

"I am extremely happy to receive this award and to be recognized by a prestigious platform like ET Healthworld. At OncoStem,we have always believed that technology has the potential to redefine cancer care and treatment. Our AI based prognostic test has helped a number early stage breast cancer patients avoid over treatment of cancer. This recognition further strengthens our commitment towards customizing breast cancer treatment by allowing low-risk patients to avoid chemotherapy," said Dr Manjiri Bakre, while commenting on the award.

OncoStem's CanAssist Breast is a prognostic test for early-stage hormone receptor positive breast cancer patients. It makes customized treatment possible by analysing the patients tumor in depth and providing a patient specific report. CanAssist Breast categorizes patients based on the risk of cancer recurrence clearly as either 'low or high' with no grey area in between.

This clear distinction of patients based on risk of cancer recurrence allows doctors to devise treatment plans that are in tune with the prognosis, maintaining a balance between the benefits and side effects. Patients who are at low risk of relapse can potentially avoid chemotherapy and its associated side-effects while patients who are at high risk of relapse would benefit from the addition of chemotherapy to their treatment regimen.

OncoStem Diagnostics develops innovative multi-marker prognostic tests to enable personalized treatment of cancer patients. OncoStem was founded by Dr Manjiri Bakre in 2011.

OncoStem's 'CanAssist Breast' is an innovative, cost-effective test that can help clinicians to plan tailor-made treatment for each breast cancer patient based on tumor biology. The risk of cancer recurrence is dependent on tumor type, stage, and on the biology of each patient's tumor. \

'CanAssist-Breast' determines the proteomic fingerprint of the tumor. This information is then used by OncoStem's proprietary machine learning-based algorithm that stratifies patients as 'low or high' risk for cancer recurrence. Patients classified as 'high-risk' would have a greater probability of cancer recurring than those classified as low-risk. This will guide clinicians in planning treatment and help patients in understanding the prognosis of their disease.

OncoStem is currently working on similar tests for other subtypes of breast cancer and ovarian cancer. OncoStem has raised approximately USD 9 million in funding from Sequoia Capital and Artiman Ventures.

This story is provided by NewsVoir. ANI will not be responsible in any way for the content of this article. (ANI/NewsVoir)

DISCLAIMER


(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Thu, September 24 2020. 23:30 IST
RECOMMENDED FOR YOU

Dr. Manjiri Bakre awarded 'Health Tech Innovator of the Year'

Bengaluru (Karnataka) [India], September 24 (ANI/NewsVoir): Dr Manjiri Bakre, Founder & CEO OncoStem Diagnostics, was awarded 'Health Tech Innovator of the Year' by ET Healthworld - Intelligent Health & Tech awards 2020.

Bengaluru (Karnataka) [India], September 24 (ANI/NewsVoir): Dr Manjiri Bakre, Founder & CEO OncoStem Diagnostics, was awarded 'Health Tech Innovator of the Year' by ET Healthworld - Intelligent Health & Tech awards 2020.

ET Healthworld.com's Intelligent Health & Tech Awards 2020 (IHTA) honours hard work, innovation and excellence of healthcare-focused AI & Tech enterprises and individuals across 30 plus categories in a number of functional areas like telemedicine services, m-health applications and medical device innovation.

It provides a platform to the game changers, innovators and achievers of AI & Tech companies, who have shown exemplary performance and have aided the growth of the healthcare industry, to claim their fame and inspire others to outshine them. Screening of applications was conducted by KPMG and some of the jury members were Dr Atul Mohan Kochhar, CEO, NABH; Dr Girdhar J Gyani, (Jury Chair), Director General, Association of Healthcare Providers India; Rakesh Mishra, Director, CSIR-CCMB Ministry of Science & Technology, Government of India and others.

"I am extremely happy to receive this award and to be recognized by a prestigious platform like ET Healthworld. At OncoStem,we have always believed that technology has the potential to redefine cancer care and treatment. Our AI based prognostic test has helped a number early stage breast cancer patients avoid over treatment of cancer. This recognition further strengthens our commitment towards customizing breast cancer treatment by allowing low-risk patients to avoid chemotherapy," said Dr Manjiri Bakre, while commenting on the award.

OncoStem's CanAssist Breast is a prognostic test for early-stage hormone receptor positive breast cancer patients. It makes customized treatment possible by analysing the patients tumor in depth and providing a patient specific report. CanAssist Breast categorizes patients based on the risk of cancer recurrence clearly as either 'low or high' with no grey area in between.

This clear distinction of patients based on risk of cancer recurrence allows doctors to devise treatment plans that are in tune with the prognosis, maintaining a balance between the benefits and side effects. Patients who are at low risk of relapse can potentially avoid chemotherapy and its associated side-effects while patients who are at high risk of relapse would benefit from the addition of chemotherapy to their treatment regimen.

OncoStem Diagnostics develops innovative multi-marker prognostic tests to enable personalized treatment of cancer patients. OncoStem was founded by Dr Manjiri Bakre in 2011.

OncoStem's 'CanAssist Breast' is an innovative, cost-effective test that can help clinicians to plan tailor-made treatment for each breast cancer patient based on tumor biology. The risk of cancer recurrence is dependent on tumor type, stage, and on the biology of each patient's tumor. \

'CanAssist-Breast' determines the proteomic fingerprint of the tumor. This information is then used by OncoStem's proprietary machine learning-based algorithm that stratifies patients as 'low or high' risk for cancer recurrence. Patients classified as 'high-risk' would have a greater probability of cancer recurring than those classified as low-risk. This will guide clinicians in planning treatment and help patients in understanding the prognosis of their disease.

OncoStem is currently working on similar tests for other subtypes of breast cancer and ovarian cancer. OncoStem has raised approximately USD 9 million in funding from Sequoia Capital and Artiman Ventures.

This story is provided by NewsVoir. ANI will not be responsible in any way for the content of this article. (ANI/NewsVoir)

DISCLAIMER


(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
image
Business Standard
177 22

Dr. Manjiri Bakre awarded 'Health Tech Innovator of the Year'

Bengaluru (Karnataka) [India], September 24 (ANI/NewsVoir): Dr Manjiri Bakre, Founder & CEO OncoStem Diagnostics, was awarded 'Health Tech Innovator of the Year' by ET Healthworld - Intelligent Health & Tech awards 2020.

ET Healthworld.com's Intelligent Health & Tech Awards 2020 (IHTA) honours hard work, innovation and excellence of healthcare-focused AI & Tech enterprises and individuals across 30 plus categories in a number of functional areas like telemedicine services, m-health applications and medical device innovation.

It provides a platform to the game changers, innovators and achievers of AI & Tech companies, who have shown exemplary performance and have aided the growth of the healthcare industry, to claim their fame and inspire others to outshine them. Screening of applications was conducted by KPMG and some of the jury members were Dr Atul Mohan Kochhar, CEO, NABH; Dr Girdhar J Gyani, (Jury Chair), Director General, Association of Healthcare Providers India; Rakesh Mishra, Director, CSIR-CCMB Ministry of Science & Technology, Government of India and others.

"I am extremely happy to receive this award and to be recognized by a prestigious platform like ET Healthworld. At OncoStem,we have always believed that technology has the potential to redefine cancer care and treatment. Our AI based prognostic test has helped a number early stage breast cancer patients avoid over treatment of cancer. This recognition further strengthens our commitment towards customizing breast cancer treatment by allowing low-risk patients to avoid chemotherapy," said Dr Manjiri Bakre, while commenting on the award.

OncoStem's CanAssist Breast is a prognostic test for early-stage hormone receptor positive breast cancer patients. It makes customized treatment possible by analysing the patients tumor in depth and providing a patient specific report. CanAssist Breast categorizes patients based on the risk of cancer recurrence clearly as either 'low or high' with no grey area in between.

This clear distinction of patients based on risk of cancer recurrence allows doctors to devise treatment plans that are in tune with the prognosis, maintaining a balance between the benefits and side effects. Patients who are at low risk of relapse can potentially avoid chemotherapy and its associated side-effects while patients who are at high risk of relapse would benefit from the addition of chemotherapy to their treatment regimen.

OncoStem Diagnostics develops innovative multi-marker prognostic tests to enable personalized treatment of cancer patients. OncoStem was founded by Dr Manjiri Bakre in 2011.

OncoStem's 'CanAssist Breast' is an innovative, cost-effective test that can help clinicians to plan tailor-made treatment for each breast cancer patient based on tumor biology. The risk of cancer recurrence is dependent on tumor type, stage, and on the biology of each patient's tumor. \

'CanAssist-Breast' determines the proteomic fingerprint of the tumor. This information is then used by OncoStem's proprietary machine learning-based algorithm that stratifies patients as 'low or high' risk for cancer recurrence. Patients classified as 'high-risk' would have a greater probability of cancer recurring than those classified as low-risk. This will guide clinicians in planning treatment and help patients in understanding the prognosis of their disease.

OncoStem is currently working on similar tests for other subtypes of breast cancer and ovarian cancer. OncoStem has raised approximately USD 9 million in funding from Sequoia Capital and Artiman Ventures.

This story is provided by NewsVoir. ANI will not be responsible in any way for the content of this article. (ANI/NewsVoir)

DISCLAIMER


(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22